000			03185nam a2200421 c4500
003			ES-MaUEC
006			a||||fo|||| 00| 0
007			cr nn nnnanaaa
710	2		_aSpringerLink (Online service) _9106996
999			_c115146 _d115146 _x1
001			115146
005			20230102113652.0
008			190831s2020 gw a o |||| 0|eng d
020			_a9783030237653
024	7		_a10.1007/978-3-030-23765-3 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC271.I45 _b2020 EB
245	0	0	_aCurrent Immunotherapeutic Strategies in Cancer _cedited by Matthias Theobald.
250			_a1st ed. 2020
264		1	_aCham _bSpringer International Publishing _c2020.
300			_a1 recurso en línea (V, 187 páginas)
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_atext file _bPDF
490	0		_aRecent Results in Cancer Research _x0080-0015 _v214
490	0		_aMedicine (Springer-11650)
505	0		_aCurrent Development of Monoclonal Antibodies in Cancer Therapy -- Clinical Experience with Bispecific T-Cell Engagers -- Advances and challenges of CAR-modified T cells in clinical trials -- Targeting Cancer with Genetically Engineered TCR-T Cells -- Tailored Vaccines Based on Patient's Cancer Mutanome -- Next-Generation Checkpoint Inhibitors and Immune Agonists.
520	3		_aThis book offers a comprehensive review of recent advances in cancer immunotherapy, and explores the value and limitations of the most effective current therapeutic strategies and emerging treatment modalities. It discusses in detail the successes achieved using monoclonal antibodies (mAbs), including developments with regard to conjugated mAbs and also bispecific mAbs as novel treatment options for leukemia and solid tumors. It also examines the advances toward personalized immunotherapy, focusing on the effectiveness of adoptive cell therapy using genetically engineered T cells with tumor-associated antigen-specific T-cell receptors and chimeric antigen receptors, as well as the role of tailored vaccines based on the patient's cancer mutanome. Further, it describes the impressive therapeutic results recently achieved with checkpoint inhibitors, and analyzes novel strategies to modulate the immunosuppressive tumor microenvironment. Written by leading international experts and providing up-to-date information on emerging strategies, such as oncolytic virus-based therapy, epigenetic therapy, and combination therapy, the book appeals to all those with an interest in immunotherapy as it comes of age.
988			_aSpringer_Medicine_2020
650		7	_aCáncer _xInmunoterapia _2embne _9348509
700	1		_aTheobald, Matthias _eeditor _4edt _4http://id.loc.gov/vocabulary/relators/edt
776	0	8	_iPrinted edition: _z9783030237646
776	0	8	_iPrinted edition: _z9783030237660
776	0	8	_iPrinted edition: _z9783030237677
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-23765-3 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_aSI _cm _dz _feng _ggw _h0 _b11/2019 _ea _zSI